Submodule
Acute Assessment and Hemodynamic Profile
Acute heart failure is a syndrome, not a single volume state. Immediate care separates oxygenation failure, congestion, low output, shock, trigger, and mimic.
- Syndrome confirmation
- Warm and wet
- Cold physiology
- Trigger search
Treat immediate threats
Guide the first pathway
Challenge mimics
Prevent recurrence
Stabilize before refining the label
Airway, oxygenation, severe respiratory distress, shock, malignant arrhythmia, ACS, mechanical complication, and hypertensive pulmonary edema can demand immediate action. Noninvasive ventilation, electrical therapy, reperfusion, or circulatory support should not wait for exhaustive taxonomy.
Use congestion and perfusion as separate axes
Warm and wet is common and favors decongestion, with vasodilation when pressure permits. Cold physiology indicates inadequate tissue flow and can occur despite preserved pressure. Cool skin, narrow pulse pressure, altered mentation, oliguria, lactate, and hepatic injury add information beyond the cuff.
Confirm heart failure and challenge mimics
Symptoms and edema are nonspecific. ECG, imaging, ultrasound, natriuretic peptide context, troponin, hemodynamics, and prior structure support the syndrome. Pneumonia, COPD, PE, renal or hepatic edema, tamponade, severe valve disease, and low-oncotic states remain active alternatives.
Treat the precipitant in parallel
Ischemia, arrhythmia, infection, uncontrolled pressure, medication or dietary change, access failure, kidney injury, anemia, thyroid disease, PE, valve dysfunction, and progressive cardiomyopathy commonly drive worsening. Decongestion without trigger control leaves recurrence risk.
Quick check
Submodule
Decongestion Strategy
Effective decongestion requires an adequate early loop dose, response measurement within hours, timely escalation, composite endpoints, and a working oral plan.
- Initial IV loop dosing
- Early response
- Sequential blockade
- Euvolemic endpoint
Cross the effective threshold
Reassess within hours
Monitor chemistry
Test the oral plan
Cross the loop threshold early
Initial IV dosing accounts for the home loop regimen, last dose, kidney function, oral absorption, severity, and prior response. A token dose below chronic exposure delays care. Measure urine output and, when protocolized, urine sodium in the first hours.
Escalate from measured failure
When response is inadequate, confirm IV delivery, true congestion, perfusion, sodium intake, NSAIDs, kidney function, and obstruction. Increase loop intensity or add a second nephron-site agent. Continuous infusion, thiazide-type therapy, or acetazolamide is selected by mechanism and monitoring capacity.
Protect chemistry during powerful diuresis
Thiazide-type sequential blockade can abruptly lower sodium, potassium, and magnesium. Acetazolamide changes bicarbonate handling and requires acid-base context. Blood pressure, kidney trajectory, urine response, and replacement needs should be reviewed at a frequency matched to intensity.
Use composite decongestion endpoints
Weight alone is noisy. Jugular pressure, orthopnea, edema, abdominal congestion, lung findings or ultrasound, symptoms, function, urine response, and organ trajectory define success. Persistent congestion at discharge carries risk even after several kilograms of weight loss.
Quick check
Submodule
Cardiorenal and Electrolyte Management
Kidney function and electrolytes move with arterial flow, venous pressure, neurohormonal state, diuretic intensity, drug exposure, and intrinsic disease.
- Creatinine trajectory
- Venous congestion
- Hyponatremia
- Potassium and magnesium
Pressure is not flow
Back pressure matters
Prevent neurologic and rhythm harm
Do not react to one value
Interpret creatinine against decongestion
A modest rise during successful volume removal can be a functional hemodynamic change rather than tubular injury. Persistent venous congestion can be more harmful. Urine output, pressure, perfusion, urinalysis, nephrotoxins, and the full trajectory distinguish the possibilities.
Treat venous pressure as kidney load
High right-sided and intra-abdominal pressure reduces renal filtration gradient and contributes to liver and gut dysfunction. A normal arterial pressure does not remove this backward pressure. Jugular findings, edema, ascites, RV function, and decongestion response matter.
Classify hyponatremia before correcting it
Confirm hypotonicity and assess symptoms, chronicity, glucose, volume, urine osmolality, urine sodium context, diuretics, kidney function, and intake. Water-excess heart failure, true depletion, and other mechanisms require different treatment, and correction must stay within current safety limits.
Protect the electrical substrate
Loop and thiazide therapy can lower potassium and magnesium. Kidney function, acid-base state, arrhythmia, digoxin, ongoing losses, and MRA or RAS therapy influence replacement. Refractory hypokalemia should prompt magnesium review.
Quick check
Submodule
Vasodilators and Inotropic Support
Vasodilators address pressure and loading in selected perfused patients. Inotropes address selected hypoperfusion and carry enough harm to require a defined endpoint and exit.
- IV nitroglycerin
- Nitroprusside
- Dobutamine
- Milrinone
Check pressure and PDE5 exposure
Monitor pressure and toxicity
Watch rate and ischemia
Adjust for kidney function
Use nitrate therapy for an appropriate pressure phenotype
IV nitroglycerin rapidly reduces venous tone and filling pressure and can support hypertensive pulmonary edema or ischemic congestion. Hypotension, right-ventricular preload dependence, recent PDE5 inhibitor exposure, headache, and tolerance shape its use.
Use nitroprusside with continuous control
Nitroprusside lowers arterial and venous load rapidly and can help selected high-afterload states. Continuous pressure monitoring is essential. Dose, duration, kidney and liver function, acid-base status, and neurologic change inform cyanide and thiocyanate risk.
Reserve dobutamine for low-output goals
Beta-adrenergic stimulation can improve contractility and flow but also causes tachyarrhythmia, ischemia, potassium change, and variable vasodilation. Beta-blocker exposure can reduce response. Escalating through tachycardia can worsen oxygen demand and filling.
Account for milrinone accumulation
PDE3 inhibition provides inotropy and vasodilation independent of beta-receptor activation. Kidney elimination makes exposure persistent in renal dysfunction. Hypotension, atrial and ventricular arrhythmia, and a longer effective offset require dose and trajectory planning.
Quick check
Submodule
Cardiogenic Shock and Advanced Support
Cardiogenic shock is a trajectory of inadequate flow. Pressure, flow, cause treatment, right and left ventricular phenotype, organ support, and a realistic bridge must be managed together.
- Shock recognition
- Norepinephrine
- Temporary mechanical support
- Advanced and palliative care
Do not wait for profound hypotension
Protect organ perfusion
Match the failing chamber
Define the exit
Recognize shock before collapse
Hypotension is important but not required for early low-output injury. Rising lactate, oliguria, altered mentation, cool skin, narrow pulse pressure, hepatic injury, and escalating vasoactive need reveal trajectory. Ischemia, mechanical complication, arrhythmia, myocarditis, PE, and RV failure require rapid cause-specific care.
Use norepinephrine to support pressure, not to declare success
Norepinephrine commonly restores perfusion pressure in hypotensive cardiogenic shock, but vasoconstriction can increase afterload. MAP, flow, lactate, urine output, mentation, ischemia, rhythm, and dose trajectory must improve together.
Match mechanical support to physiology
Temporary support selection follows LV versus RV failure, oxygenation, cause, bleeding and vascular risk, neurologic and organ trajectory, center capability, and the intended bridge. Device placement without a recovery, decision, durable-support, transplant, or palliation pathway is incomplete care.
Integrate advanced and palliative planning
Recurrent admissions, inotrope dependence, organ dysfunction, frailty, escalating diuretics, or therapy intolerance should prompt early advanced-heart-failure and palliative evaluation. Symptom support, caregiver support, preparedness, transplant, durable support, and patient goals can be discussed in parallel.
Quick check
Submodule
Hospital-to-Home Transition
The discharge transition is a therapeutic phase that tests oral decongestion, establishes disease therapy, assigns laboratory and follow-up ownership, and solves access barriers.
- Inpatient disease therapy
- SGLT2 initiation
- Oral diuretic test
- Early follow-up
Explain every change
Avoid an untested plan
Name the owner
Make the plan executable
Preserve and establish disease therapy
Beta-blocker, ARNI or RAS therapy, MRA, and SGLT2 decisions follow prior tolerance, current compensation, pressure, kidney function, potassium, shock, and metabolic stability. A temporary hold needs a documented restart plan rather than silent therapeutic loss.
Use the hospital as an initiation opportunity
SGLT2 therapy can begin after stabilization across ejection-fraction phenotypes if oral intake, fasting or surgery, ketoacidosis risk, kidney function, infection, and volume are addressed. HFrEF pillars should be established before discharge when safe.
Test the oral congestion plan
Observe response to the intended oral loop regimen. Reconcile equivalent dose, timing, target weight, potassium plan, scale and bathroom access, affordability, and instructions for adjustment. Discharge directly after IV therapy leaves oral failure untested.
Make follow-up executable
Provide exact early visit and laboratory dates, responsible clinicians, symptom and weight thresholds, pharmacy access, and a concise explanation of diagnosis, trigger, and every medication change. Transportation, literacy, language, cognition, and caregiver support require specific solutions.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.